Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































Comparison of State Prescription Drug Affordability Review Initiatives
/in Prescription Drug Pricing Maine, Maryland, Massachusetts, New Hampshire, New York, Ohio Charts, Featured News Home Administrative Actions, Legal Resources, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP Staff2022 State of the State Addresses Reflect Realities of Health, Economic Recovery
/in Health Coverage and Access Blogs Chronic and Complex Populations, Cost, Payment, and Delivery Reform, Featured Policy Home, Health Coverage and Access, Health System Costs, Maternal, Child, and Adolescent Health, Population Health, Prescription Drug Pricing /by Allie Atkeson, Anita Cardwell, Clare Cartheuser, Rebecca Cooper, Gia Gould and Elinor HigginsDrug Price Transparency Laws Position States to Impact Drug Prices
/in Prescription Drug Pricing California, Maine, Nevada, Oregon, Vermont Blogs, Featured News Home Prescription Drug Pricing /by Johanna Butler and Jennifer ReckDrug price transparency laws enable state policymakers to understand opaque drug pricing and payment systems to formulate appropriate policy solutions to high prices, while also creating the data infrastructure to effectively realize those policy solutions. Since Vermont passed the first state drug price transparency law in 2016, more than a dozen states have enacted and […]
Toolkit: New Legislative and Medicaid Models to Lower Drug Prices
/in Prescription Drug Pricing Featured News Home, Toolkits Legal Resources, Model Legislation, Prescription Drug Pricing /by Drew Gattine, Jennifer Reck and Sarah LanfordState Strategies To Lower Drug Prices: New Legislative And Medicaid Models
/in Prescription Drug Pricing Featured News Home, Reports Prescription Drug Pricing /by Sarah Lanford, Jennifer Reck and Drew GattineOpportunities for Aligning Prescription Drug Affordability Boards and Cost-Growth Benchmarks
/in Prescription Drug Pricing Blogs Prescription Drug Pricing /by Johanna ButlerHigh prices for health care services and prescription drugs are driving health care spending and increasing insurance premiums. To tackle rising health care costs, states have advanced two separate but related initiatives over the past few years: cost-growth benchmarks to track and contain overall health care spending; and prescription drug affordability boards (PDABs) to conduct […]
NASHP’s Annual Conference Highlights States Taking Bold Action on Drug Prices
/in Prescription Drug Pricing Featured News Home Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Sarah Lanford and Jennifer ReckWhile Congress continues to consider significant reforms for drug pricing, states have taken bold steps to control drug prices across payers. This legislative session, Colorado followed Maryland’s lead and established a prescription drug affordability board (PDAB) to address high drug prices. PDAB legislation, such as Maryland’s and Colorado’s, that includes authority for a board to […]
States Can Again Weigh in on TennCare Demonstration with Closed Formulary
/in Prescription Drug Pricing Blogs, Featured News Home Prescription Drug Pricing /by Jennifer ReckStates and other stakeholders have another chance to weigh in on Tennessee’s 10-year Medicaid funding demonstration which was approved by the Centers for Medicare & Medicaid Services (CMS) in early January during the final days of the Trump administration. In April, two legal advocacy organizations sued the federal government to block the demonstration, though the plaintiffs have since agreed to pause the lawsuit on the condition that a new federal […]
Three More States Enact Reverse Auction Laws to Reduce Prescription Drug Spending
/in Prescription Drug Pricing Colorado, Louisiana, Minnesota Blogs, Featured News Home Prescription Drug Pricing /by Amanda AttiyaColorado, Louisiana, and Minnesota enacted laws this session enabling reverse auctions to procure a pharmacy benefit manager (PBM) for their state employee health plans (SEHPs). This approach to PBM procurement, first used by New Jersey, aims to achieve savings by encouraging PBMs to be more competitive on pricing in their bidding for contracts without reducing drug benefits for the state’s public employees. In the reverse auction procurement model, states design their own […]
State Strategies for Costly Drugs with Unconfirmed Clinical Benefits
/in Prescription Drug Pricing Blogs, Featured News Home Prescription Drug Pricing /by Jennifer Reck and Amanda AttiyaThe recent approval of the Alzheimer’s drug Aduhelm under the U.S. Food & Drug Administration’s (FDA) Accelerated Approval Program is controversial for a range of reasons, including its projected impact on state Medicaid budgets which will be required to cover the drug, priced at $56,000 a year, despite inconclusive evidence of its clinical effectiveness. While Aduhelm is the latest prescription drug to make headlines, state Medicaid programs have been seeking policy solutions to address high cost accelerated […]